Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) is a heterogeneous blood cancer with variable outcomes.
• Established prognostic biomarkers guide CLL treatment and understanding.
• The roles of B cell regulators BACH2 and BCL6 in CLL prognosis require further investigation.

Purpose of the Study:

• To investigate the clinical significance of BACH2 and BCL6 in CLL.
• To identify protein interaction networks involving BACH2 and BCL6 in CLL cells.
• To assess the prognostic value of BACH2 and BCL6 expression in CLL patients.

Main Methods:

• Analysis of BACH2 and BCL6 RNA and protein expression in 102 CLL patients.
• Determination of protein interaction networks using MEC-1 CLL cells.
• Development of a prognostic index (PI) model integrating BACH2 expression, age, and 17p deletion.

Main Results:

• Low BCL6 and BACH2 RNA expression correlated with significantly shorter overall survival (OS).
• Low expression particularly impacted OS in immunoglobulin heavy chain variable region-mutated (IGHV-M) CLL and those with 11q/13q deletions.
• Low BACH2 protein expression also associated with shorter OS.
• BACH2 and BCL6 shared protein networks involving 50 proteins, implicated in B cell receptor function, nucleic acid metabolism, and protein degradation.
• A PI model using BACH2 RNA, age, and 17p deletion predicted patient outcomes.

Conclusions:

• BACH2 may serve as a novel prognostic biomarker in CLL.
• BACH2 and BCL6 play significant roles in key cellular processes within CLL.
• Shared protein networks suggest coordinated functions of BACH2 and BCL6 in CLL biology.